Liberia study's 27,000 enrollment 'no longer makes sense'
This article was originally published in Scrip
Executive Summary
Because of the decline in Ebola cases in West Africa, reaching the 27,000 enrollment goal for a Phase III study to test two experimental vaccines against the virus in Liberia "no longer makes sense," the US lead investigator of the so-called PREVAIL study acknowledged.